Free tool
FAERS Monitor: Nucala
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125526 or its brand name (Nucala, Mepolizumab). Reports on generic versions are filed under their own applications.
Reports
50,431
Serious
31,676
63% of reports
Hospitalization
16,281
Death reported
4,180
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma12,892
- dyspnoea10,717
- wheezing7,204
- product dose omission issue6,869
- cough5,147
- therapeutic product effect incomplete5,092
- drug ineffective4,736
- pneumonia4,726
- loss of personal independence in daily activities4,281
- fatigue3,151
- sleep disorder due to a general medical condition3,148
- off label use3,137
- malaise2,828
- condition aggravated2,813
- headache2,774
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 18 |
| 2016 | 579 |
| 2017 | 1,547 |
| 2018 | 3,014 |
| 2019 | 4,612 |
| 2020 | 5,676 |
| 2021 | 6,089 |
| 2022 | 4,725 |
| 2023 | 5,642 |
| 2024 | 7,767 |
| 2025 | 7,636 |
| 2026 | 3,110 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,728 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep disorder due to a general medical conditionSignal | 3,148 | 94.7 | 91.1 | 237,796 |
| wheezingSignal | 7,204 | 57.5 | 56.2 | 352,509 |
| asthmaSignal | 12,892 | 53.6 | 52.7 | 592,388 |
| loss of personal independence in daily activitiesSignal | 4,281 | 40.7 | 39.5 | 151,350 |
| therapeutic product effect incompleteSignal | 5,092 | 32.1 | 31.2 | 142,797 |
| product dose omission issueSignal | 6,869 | 10.0 | 9.7 | 54,772 |
| dyspnoeaSignal | 10,717 | 8.0 | 7.9 | 66,478 |
| coughSignal | 5,147 | 7.8 | 7.6 | 30,245 |
| pneumoniaSignal | 4,726 | 6.2 | 6.0 | 20,454 |
| condition aggravatedSignal | 2,813 | 3.9 | 3.7 | 6,057 |
| malaiseSignal | 2,828 | 2.7 | 2.6 | 3,070 |
| headache | 2,774 | 1.8 | 1.8 | 1,109 |
| fatigue | 3,151 | 1.7 | 1.6 | 919 |
| drug ineffective | 4,736 | 1.5 | 1.5 | 840 |
| off label use | 3,137 | 1.5 | 1.4 | 536 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.